<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04047862</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-900-105</org_study_id>
    <nct_id>NCT04047862</nct_id>
  </id_info>
  <brief_title>Study of BGB-A1217 in Combination With Tislelizumab in Advanced Solid Tumors</brief_title>
  <official_title>Phase 1/1b Study Investigating Safety, Tolerability, PK and Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      BGB-A1217 is a humanized, IgG1 monoclonal antibody against TIGIT. Tislelizumab is a
      humanized, IgG4-variant monoclonal antibody against PD-1. This study tests the safety and
      anti-tumor effect of BGB-A1217 in combination with tislelizumab in patients with advanced
      solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 26, 2019</start_date>
  <completion_date type="Anticipated">April 5, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 5, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1 Dose Escalation - Safety and tolerability of BGB-A1217 in combination with tislelizumab using Common Terminology Criteria for Adverse Events (CTCAE v.5.0) in patients with advanced solid tumors.</measure>
    <time_frame>Up to 1.5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1 Dose Escalation - Recommended Phase Ib dose (RP2D) of BGB-A1217 in combination with tislelizumab</measure>
    <time_frame>Up to 1.5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1b Dose Confirmation - Anti-tumor activity of BGB-1217 in combination with tislelizumab in patients with select advanced solid tumors, in terms of objective response rate (ORR) as assessed by the Investigators using RECIST v. 1.1.</measure>
    <time_frame>Up to 1.5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Duration of response (DOR) will be determined from investigator derived tumor assessments per RECIST v. 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Disease control rate (DCR) will be determined from investigator derived tumor assessments per RECIST v. 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Progression free survival will be determined from investigator derived tumor assessments per RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Immunogenicity as assessed by the presence of anti-drug antibodies</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Metastatic Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Phase 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A modified 3+3 scheme will be used for sequential cohorts of approximately 5 increasing dose levels of BGB-A1217, evaluated in combination with 200 mg of tislelizumab, to determine the MTD or MAD, RP2D, safety, PK, and other key endpoints.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGB-A1217</intervention_name>
    <description>Dose escalation of BGB-A1217 in combination with tislelizumab in patients with advanced solid tumors</description>
    <arm_group_label>Phase 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tislelizumab</intervention_name>
    <description>Dose escalation of BGB-A1217 in combination with tislelizumab in patients with advanced solid tumors</description>
    <arm_group_label>Phase 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with histologically or cytologically confirmed advanced, metastatic,
             unresectable solid tumors who have previously received standard systemic therapy or
             for which treatment is not available, not tolerated or refused.

          2. Has Eastern Cooperative Oncology Group (ECOG) Performance Status â‰¤1.

          3. Has adequate organ function.

        Exclusion Criteria:

          1. Active brain or leptomeningeal metastasis.

          2. Active autoimmune diseases or history of autoimmune diseases that may relapse.

          3. With severe chronic or active infections requiring systemic antibacterial, antifungal
             or antiviral therapy, including tuberculosis infection, etc. (antiviral therapy is
             permitted for patients with hepatocellular carcinoma).

          4. Concurrent participation in another therapeutic clinical trial.

          5. Received prior therapies targeting TIGIT.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tarek Meniawy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Linear Clinical Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BeiGene</last_name>
    <phone>1-877-828-5568</phone>
    <email>clinicaltrials@beigene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chris O'Brien Lifehouse</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Monash Hospital</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 1, 2019</study_first_submitted>
  <study_first_submitted_qc>August 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2019</study_first_posted>
  <last_update_submitted>November 1, 2019</last_update_submitted>
  <last_update_submitted_qc>November 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BGB-A1217</keyword>
  <keyword>Anti-TIGIT antibody</keyword>
  <keyword>Tislelizumab</keyword>
  <keyword>anti-PD-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

